235 related articles for article (PubMed ID: 34553295)
1. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
Malin D; Lee Y; Chepikova O; Strekalova E; Carlson A; Cryns VL
Breast Cancer Res Treat; 2021 Dec; 190(3):373-387. PubMed ID: 34553295
[TBL] [Abstract][Full Text] [Related]
2. Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
Chepikova OE; Malin D; Strekalova E; Lukasheva EV; Zamyatnin AA; Cryns VL
Breast Cancer Res Treat; 2020 Oct; 183(3):549-564. PubMed ID: 32696316
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
Yan X; Zhang X; Wang L; Zhang R; Pu X; Wu S; Li L; Tong P; Wang J; Meng QH; Jensen VB; Girard L; Minna JD; Roth JA; Swisher SG; Heymach JV; Fang B
Cancer Res; 2019 Jan; 79(1):125-132. PubMed ID: 30401714
[TBL] [Abstract][Full Text] [Related]
5. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E; Malin D; Good DM; Cryns VL
Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
[TBL] [Abstract][Full Text] [Related]
6. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
Yin C; Dai X; Huang X; Zhu W; Chen X; Zhou Q; Wang C; Zhao C; Zou P; Liang G; Rajamanickam V; Wang O; Zhang X; Cui R
J Cell Mol Med; 2019 Mar; 23(3):2194-2206. PubMed ID: 30609207
[TBL] [Abstract][Full Text] [Related]
7. Selenium-independent antioxidant and anti-inflammatory effects of thioredoxin reductase inhibition in alveolar macrophages.
Staples S; Wall SB; Li R; Tipple TE
Life Sci; 2020 Oct; 259():118285. PubMed ID: 32798556
[TBL] [Abstract][Full Text] [Related]
8. The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms.
Dunigan K; Li Q; Li R; Locy ML; Wall S; Tipple TE
Am J Physiol Lung Cell Mol Physiol; 2018 Oct; 315(4):L545-L552. PubMed ID: 30024305
[TBL] [Abstract][Full Text] [Related]
9. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
Lee D; Xu IM; Chiu DK; Leibold J; Tse AP; Bao MH; Yuen VW; Chan CY; Lai RK; Chin DW; Chan DF; Cheung TT; Chok SH; Wong CM; Lowe SW; Ng IO; Wong CC
Hepatology; 2019 Apr; 69(4):1768-1786. PubMed ID: 30561826
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models.
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Cancer Genomics Proteomics; 2024; 21(2):178-185. PubMed ID: 38423598
[TBL] [Abstract][Full Text] [Related]
11. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
[TBL] [Abstract][Full Text] [Related]
13. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.
Stafford WC; Peng X; Olofsson MH; Zhang X; Luci DK; Lu L; Cheng Q; Trésaugues L; Dexheimer TS; Coussens NP; Augsten M; Ahlzén HM; Orwar O; Östman A; Stone-Elander S; Maloney DJ; Jadhav A; Simeonov A; Linder S; Arnér ESJ
Sci Transl Med; 2018 Feb; 10(428):. PubMed ID: 29444979
[TBL] [Abstract][Full Text] [Related]
14. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
Dai B; Yoo SY; Bartholomeusz G; Graham RA; Majidi M; Yan S; Meng J; Ji L; Coombes K; Minna JD; Fang B; Roth JA
Cancer Res; 2013 Sep; 73(17):5532-43. PubMed ID: 23824739
[TBL] [Abstract][Full Text] [Related]
15. The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Tsukanishi T; Ohtori S; Yonemoto T
Anticancer Res; 2021 Oct; 41(10):4947-4955. PubMed ID: 34593442
[TBL] [Abstract][Full Text] [Related]
16. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose.
Du Y; Zhang H; Lu J; Holmgren A
J Biol Chem; 2012 Nov; 287(45):38210-9. PubMed ID: 22977247
[TBL] [Abstract][Full Text] [Related]
17. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin.
Isakov E; Weisman-Shomer P; Benhar M
Biochim Biophys Acta; 2014 Oct; 1840(10):3153-61. PubMed ID: 25065288
[TBL] [Abstract][Full Text] [Related]
20. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
